Advancing nonclinical innovation and safety in pharmaceutical testing

Area of Science:

• Pharmacology
• Toxicology
• Drug Development

Background:

• Nonclinical tests are vital for assessing investigational medicine safety.
• Current translation of nonclinical findings to human application is limited.
• There is a need to improve the predictive accuracy of preclinical safety assessments.

Purpose of the Study:

• To highlight the limitations of traditional nonclinical testing in drug development.
• To advocate for the advancement and integration of human-based testing methods.
• To propose actionable recommendations for improving the translation of drug safety data.

Main Methods:

• Review of current drug development practices and limitations.
• Analysis of the potential of in vitro and in silico human-based methods.
• Formulation of recommendations based on stakeholder input and scientific rationale.

Main Results:

• Human-based in vitro and in silico methods can model direct drug interactions with human systems.
• These methods offer potentially greater predictability of human efficacy and safety.
• Current regulatory and funding landscapes present barriers to adoption.

Conclusions:

• Test-neutral regulations are recommended to foster innovation.
• Increased funding and support for human-based approaches are essential.
• Establishing guidelines for human cell/tissue procurement and training are crucial for successful implementation.